You are here

Article Text

Article menu
Download PDFPDF
Correspondence
Next frontier in management of atrial fibrillation
  1. Nicole Lowres1,2,
  2. Katrina Giskes1,3,
  3. Ben Freedman1,2,4
  1. 1 Heart Research Institute, Charles Perkins Centre, University of Sydney, Sydney, NSW, Australia
  2. 2 Faculty of Medicine and Heath, University of Sydney, Sydney, NSW, Australia
  3. 3 Faculty of Medicine, University of Notre Dame, Sydney, NSW, Australia
  4. 4 Dept of Cardiology, Concord Hospital, Sydney, NSW, Australia
  1. Correspondence to Professor Ben Freedman, Charles Perkins Centre, Heart Research Institute University of Sydney, Sydney, NSW 2006, Australia; ben.freedman{at}sydney.edu.au

https://doi.org/10.1136/heartjnl-2021-318961

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    The Authors' reply

    Our editorial1 outlines five important steps in the management of atrial fibrillation (AF), of which guideline-based diagnosis and assessment is step 2. Our editorial focuses on the fourth and fifth management steps, as these steps relate to the article which the editorial was written to accompany - the stroke penalty of stopping oral anticoagulant.2 Once patients with AF receive a thorough assessment …

    View Full Text

    Footnotes

    • Twitter @NicoleLowres

    • Contributors All authors contributed equally to the concepts and assisted with drafting the article.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests NL reports grants from BMS/Pfizer outside the submitted work. KG has received honoraria from Pfizer for professional activities outside the submitted work. BF reports grants, personal fees and non-financial support from BMS/Pfizer; grants, personal fees and non-financial support from Bayer; personal fees and non-financial support from Daiichi Sankyo; non-financial support from Alivecor; and personal fees and non-financial support from Omron outside the submitted work.

    • Patient and public involvement Patients and/or the public were not involved in the design, conduct, reporting or dissemination plans of this research.

    • Provenance and peer review Commissioned; internally peer reviewed.

    Linked Articles